The results of the @-week study of dupilumab monotherapy reproduced and extended the @-week findings : @ % of patients in the dupilumab group , as compared with @ % of those in the placebo group , had a @ % reduction in the EASI score ( EASI-@ , with higher scores in the EASI indicating greater severity of eczema ) ( P < @ ) ; @ % of patients in the dupilumab group , as compared with @ % in the placebo group , had a score of @ to @ ( indicating clearing or near-clearing of skin lesions ) on the investigator 's global assessment ( P < @ ) ; and pruritus scores decreased ( indicating a reduction in itch ) by @ % in the dupilumab group versus @ % in the placebo group ( P < @ ) .